Revolutionizing Obesity Treatment: Sedivention Secures €2.9M for Minimally Invasive Therapy

The global obesity epidemic is poised to affect over a billion people, with current treatment options often falling short due to their invasive nature, high costs, or the need for long-term medication. However, a breakthrough in medical technology could change the landscape. Sedivention, a medtech startup from Germany, has raised €2.9 million in seed funding to advance its innovative, one-time outpatient therapy for obesity. This minimally invasive procedure uses cryoablation to target the vagus nerve, potentially offering a lasting reduction in hunger without the need for surgery or lifelong medication.



Sedivention's approach is built around a specially designed balloon catheter, similar to those used in gastroscopy, which delivers precise cryoablation to interrupt hunger-related signals. This method addresses the underlying physiological mechanisms of obesity, aiming for sustained appetite reduction. The significance of this development cannot be overstated, as it promises to fill a critical gap in the treatment of obesity. Existing treatments, including bariatric surgery and drug therapies, have limitations that Sedivention's therapy could overcome.



The funding round, led by bmp Ventures alongside the IBG funds, also includes investments from the strategic investment arm of a global medtech company, High-Tech Gründerfonds (HTGF), superangels, and Cambridge Ventures. This diverse backing underscores the potential of Sedivention's technology to transform the obesity treatment landscape. Dr. Ute Nollert, founder and Chief Medical Officer of Sedivention, emphasizes the need for treatments that are both clinically effective and minimally invasive, highlighting the company's focus on addressing the root causes of obesity.



The implications of Sedivention's therapy extend beyond the medical community to everyday individuals struggling with obesity. For those affected, this could mean access to a more dignified, less invasive treatment option that doesn't require a lifetime commitment to medication or the risks associated with surgery. From an industry perspective, Sedivention's approach could reshape how obesity is treated, potentially reducing the economic burden on healthcare systems and improving patient outcomes.



As Sedivention moves forward with its plans to advance product development, generate initial clinical data, and prepare for regulatory and market entry, the potential for this technology to make a significant impact on global health becomes increasingly clear. The shift towards minimally invasive, effective treatments for chronic conditions like obesity could redefine the future of healthcare, making access to quality care more equitable and less daunting for those in need.



In conclusion, Sedivention's innovative therapy and the funding it has secured represent a beacon of hope in the fight against obesity. By targeting the root causes of the condition and offering a minimally invasive solution, Sedivention is poised to make a lasting impact on the lives of millions worldwide.